Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Core Insights - Armata Pharmaceuticals has secured a $10 million credit agreement with Innoviva, its largest shareholder, to advance the development of its phage product candidates [1][3] - The financing will support the clinical development of lead therapeutic phage candidates AP-PA02 and AP-SA02, targeting infections from Pseudomonas aeruginosa and Staphylococcus aureus [2][3] - The secured credit agreement includes a term loan facility with a 14.0% annual interest rate, maturing on March 12, 2026 [3][4] Company Overview - Armata Pharmaceuticals is a clinical-stage biotechnology company focused on high-purity pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections [5] - The company is developing a pipeline of natural and synthetic phage candidates, including those for Pseudomonas aeruginosa and Staphylococcus aureus [5] - Armata is committed to advancing phage therapy with expertise in drug development and in-house cGMP manufacturing [5]